The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid funding, ...

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.

The head of the U.N. AIDS agency said Monday that the sudden loss of American money has been “devastating” for efforts to ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...

Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is ...

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the ...

A main obstacle to an HIV cure is that viral DNA integrates into the chromosomes of memory T cells (blue), which evade ...

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...